ATE401097T1 - Verwendung von imidazochinolinaminen als adjuvantien in dna-impfung - Google Patents
Verwendung von imidazochinolinaminen als adjuvantien in dna-impfungInfo
- Publication number
- ATE401097T1 ATE401097T1 AT01967535T AT01967535T ATE401097T1 AT E401097 T1 ATE401097 T1 AT E401097T1 AT 01967535 T AT01967535 T AT 01967535T AT 01967535 T AT01967535 T AT 01967535T AT E401097 T1 ATE401097 T1 AT E401097T1
- Authority
- AT
- Austria
- Prior art keywords
- imidazocinolinamines
- adjuvants
- dna vaccination
- vaccination
- dna
- Prior art date
Links
- 238000011238 DNA vaccination Methods 0.000 title 1
- 239000002671 adjuvant Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0023008.6A GB0023008D0 (en) | 2000-09-20 | 2000-09-20 | Improvements in vaccination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE401097T1 true ATE401097T1 (de) | 2008-08-15 |
Family
ID=9899764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01967535T ATE401097T1 (de) | 2000-09-20 | 2001-09-20 | Verwendung von imidazochinolinaminen als adjuvantien in dna-impfung |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20040076633A1 (de) |
| EP (1) | EP1318835B1 (de) |
| JP (1) | JP2004509150A (de) |
| KR (1) | KR100876263B1 (de) |
| CN (1) | CN1197620C (de) |
| AR (1) | AR035586A1 (de) |
| AT (1) | ATE401097T1 (de) |
| AU (2) | AU8790801A (de) |
| BR (1) | BR0113982A (de) |
| CA (1) | CA2422863A1 (de) |
| CZ (1) | CZ2003792A3 (de) |
| DE (1) | DE60134866D1 (de) |
| ES (1) | ES2309086T3 (de) |
| GB (1) | GB0023008D0 (de) |
| HU (1) | HUP0301180A3 (de) |
| IL (1) | IL154947A0 (de) |
| MX (1) | MXPA03002453A (de) |
| MY (1) | MY138978A (de) |
| NO (1) | NO20031274L (de) |
| NZ (1) | NZ524792A (de) |
| PL (1) | PL360895A1 (de) |
| TW (1) | TWI287453B (de) |
| WO (1) | WO2002024225A1 (de) |
| ZA (1) | ZA200302231B (de) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| SI1077722T1 (sl) | 1998-05-22 | 2007-02-28 | Ottawa Health Research Inst | Metode in produkti za induciranje sluznicne imunosti |
| US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
| GB0206461D0 (en) * | 2002-03-19 | 2002-05-01 | Glaxo Group Ltd | Improvements in vaccination |
| DK1487485T3 (da) * | 2002-03-19 | 2011-03-14 | Powderject Res Ltd | Imidazoquinolinadjuvanser til DNA-vacciner |
| CA2484044A1 (en) * | 2002-03-19 | 2003-10-02 | Powdermed Limited | Imidazoquinolineamines as adjuvants in hiv dna vaccination |
| DK1545597T3 (da) * | 2002-08-15 | 2011-01-31 | 3M Innovative Properties Co | Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons |
| CA2510375A1 (en) | 2002-12-20 | 2004-07-15 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
| US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
| BRPI0413558A (pt) * | 2003-08-12 | 2006-10-17 | 3M Innovative Properties Co | compostos contendo imidazo substituìdo por hidroxilamina |
| JP2007504145A (ja) * | 2003-08-25 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫刺激性の組み合わせおよび治療 |
| US8961477B2 (en) * | 2003-08-25 | 2015-02-24 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
| AU2004268625B2 (en) | 2003-08-27 | 2011-03-31 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
| AU2004270201A1 (en) * | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for CD5+ B cell lymphoma |
| AR046046A1 (es) | 2003-10-03 | 2005-11-23 | 3M Innovative Properties Co | Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas. |
| US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| US20090075980A1 (en) * | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
| EP1685129A4 (de) | 2003-11-14 | 2008-10-22 | 3M Innovative Properties Co | Oximsubstituierte imidazoringverbindungen |
| CA2545825A1 (en) * | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo ring compounds |
| CA2547020C (en) | 2003-11-25 | 2014-03-25 | 3M Innovative Properties Company | 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier |
| JP2007517035A (ja) * | 2003-12-29 | 2007-06-28 | スリーエム イノベイティブ プロパティズ カンパニー | アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン |
| EP1699788A2 (de) * | 2003-12-30 | 2006-09-13 | 3M Innovative Properties Company | Imidazochinolinyl-, imidazopyridinyl- und imidazonaphthyridinylsulfonamide |
| WO2005094531A2 (en) * | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| US8017779B2 (en) * | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
| US8026366B2 (en) * | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
| US20070259881A1 (en) * | 2004-06-18 | 2007-11-08 | Dellaria Joseph F Jr | Substituted Imidazo Ring Systems and Methods |
| WO2006065280A2 (en) * | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
| WO2006038923A2 (en) * | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
| US20090270443A1 (en) * | 2004-09-02 | 2009-10-29 | Doris Stoermer | 1-amino imidazo-containing compounds and methods |
| EP1804583A4 (de) * | 2004-10-08 | 2009-05-20 | 3M Innovative Properties Co | Adjuvans für dna-impfstoffe |
| DE102004049223A1 (de) | 2004-10-08 | 2006-04-20 | Johannes-Gutenberg-Universität Mainz | Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung |
| EP1819364A4 (de) * | 2004-12-08 | 2010-12-29 | 3M Innovative Properties Co | Immunmodulatorische zusammensetzungen, kombinationen und verfahren |
| PL1830876T3 (pl) * | 2004-12-30 | 2015-09-30 | Meda Ab | Zastosowanie imikwimodu do leczenia przerzutów do skóry wywodzących się od guza stanowiącego raka piersi |
| JP5543068B2 (ja) * | 2004-12-30 | 2014-07-09 | スリーエム イノベイティブ プロパティズ カンパニー | キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物 |
| EP1831221B1 (de) | 2004-12-30 | 2012-08-08 | 3M Innovative Properties Company | Substituierte, chirale, fusionierte 1,2 imidazo-4,5-c-ringverbindungen |
| AU2006210392A1 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune response modifiers |
| AU2006213746A1 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods |
| EP1869043A2 (de) | 2005-04-01 | 2007-12-26 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridin-1,4-diamine und analoge davon |
| AU2006232375A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
| CN101304748A (zh) | 2005-08-22 | 2008-11-12 | 加利福尼亚大学董事会 | Tlr激动剂 |
| ZA200803029B (en) * | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
| EA200800782A1 (ru) * | 2005-09-09 | 2008-08-29 | Коли Фармасьютикал Груп, Инк. | ПРОИЗВОДНЫЕ АМИДА И КАРБАМАТА N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗОЛО[4,5-c]ХИНОЛИН-1-IL]-1,1-ДИМЕТИЛЭТИЛ}МЕТАНСУЛЬФОНАМИДА И СПОСОБЫ |
| KR20080083270A (ko) | 2005-11-04 | 2008-09-17 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법 |
| EP1988896A4 (de) | 2006-02-22 | 2011-07-27 | 3M Innovative Properties Co | Konjugate zur modifizierung von immunreaktionen |
| US8088788B2 (en) | 2006-03-15 | 2012-01-03 | 3M Innovative Properties Company | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods |
| US8329721B2 (en) * | 2006-03-15 | 2012-12-11 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods |
| CA2645832A1 (en) * | 2006-04-25 | 2007-11-01 | Intercell Ag | Hcv vaccinations |
| US20090060928A1 (en) * | 2006-05-26 | 2009-03-05 | Jean-Claude Bystryn | Topical Toll Like Receptor Ligands as Vaccine Adjuvants |
| EP2700638A1 (de) | 2006-05-31 | 2014-02-26 | The Regents Of the University of California | Purinanaloga |
| MX2008016036A (es) * | 2006-06-20 | 2009-04-07 | Transgene Sa | Vacuna viral recombinante. |
| ES2444695T3 (es) | 2006-06-23 | 2014-02-26 | Alethia Biotherapeutics Inc. | Polinucleótidos y polipéptidos implicados en el cáncer |
| US7906506B2 (en) * | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
| CN100450484C (zh) * | 2006-10-11 | 2009-01-14 | 北京科信必成医药科技发展有限公司 | 一种咪喹莫特混悬溶液及其凝胶剂 |
| CN101790380B (zh) | 2007-02-07 | 2013-07-10 | 加利福尼亚大学董事会 | 合成tlr激动剂的缀合物及其应用 |
| CN103736086A (zh) * | 2007-02-15 | 2014-04-23 | 曼康公司 | 用于增强t细胞应答的方法 |
| US8709445B2 (en) | 2007-07-31 | 2014-04-29 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Vaccination with killed but metabolically active (KBMA) protozoans with toll-like receptor agonists |
| EP3067048B1 (de) | 2007-12-07 | 2018-02-14 | GlaxoSmithKline Biologicals SA | Zusammensetzungen zur induzierung von immunreaktionen |
| CA2740900C (en) | 2008-11-03 | 2019-09-24 | Alethia Biotherapeutics Inc. | Antibodies that specifically block the biological activity of a tumor antigen |
| WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| EP2508190B1 (de) * | 2009-12-03 | 2021-06-02 | Aureo Co., Ltd. | Makrophagen-phagozytose-aktivierende zusammensetzung und/oder zusammensetzung zur förderung der zytokinproduktion in makrophagen |
| CN101850117B (zh) * | 2010-06-03 | 2012-05-30 | 国家兽用生物制品工程技术研究中心 | 一种复方免疫佐剂及疫苗 |
| US9242980B2 (en) | 2010-08-17 | 2016-01-26 | 3M Innovative Properties Company | Lipidated immune response modifier compound compositions, formulations, and methods |
| SI3173427T1 (sl) | 2011-03-31 | 2019-08-30 | ADC Therapeutics SA, | Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega |
| JP6460789B2 (ja) | 2011-06-03 | 2019-01-30 | スリーエム イノベイティブ プロパティズ カンパニー | ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体 |
| BR112013031039B1 (pt) | 2011-06-03 | 2020-04-28 | 3M Innovative Properties Co | compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado |
| KR102102239B1 (ko) | 2012-01-09 | 2020-04-21 | 에이디씨 테라퓨틱스 에스에이 | 유방암을 치료하기 위한 방법 |
| GB201310578D0 (en) | 2013-06-13 | 2013-07-31 | Univ Nottingham Trent | Electroactive actuators |
| WO2015023649A2 (en) | 2013-08-12 | 2015-02-19 | 3M Innovative Properties Company | Peptides for enhancing transdermal delivery |
| JP7145757B2 (ja) | 2015-10-12 | 2022-10-03 | リフロー メディカル インコーポレイテッド | 突出する薬剤送達フィーチャーを有するステント、ならびに、関連のシステムおよび方法 |
| US10533007B2 (en) | 2016-04-19 | 2020-01-14 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| KR20180134395A (ko) | 2016-04-19 | 2018-12-18 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
| US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| WO2018217897A1 (en) * | 2017-05-23 | 2018-11-29 | David Weiner | Compositions and method for inducing an immune response |
| US11524069B2 (en) | 2017-09-13 | 2022-12-13 | Sanofi Pasteur | Human cytomegalovirus immunogenic composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| IL105325A (en) * | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| KR100564268B1 (ko) * | 1996-10-23 | 2006-03-27 | 와이어쓰 | 백신 |
| GB9818627D0 (en) * | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Improvements in dva vaccination |
-
2000
- 2000-09-20 GB GBGB0023008.6A patent/GB0023008D0/en not_active Ceased
-
2001
- 2001-09-20 BR BR0113982-7A patent/BR0113982A/pt not_active Application Discontinuation
- 2001-09-20 HU HU0301180A patent/HUP0301180A3/hu unknown
- 2001-09-20 IL IL15494701A patent/IL154947A0/xx unknown
- 2001-09-20 EP EP01967535A patent/EP1318835B1/de not_active Revoked
- 2001-09-20 DE DE60134866T patent/DE60134866D1/de not_active Expired - Lifetime
- 2001-09-20 CZ CZ2003792A patent/CZ2003792A3/cs unknown
- 2001-09-20 MX MXPA03002453A patent/MXPA03002453A/es active IP Right Grant
- 2001-09-20 US US10/380,981 patent/US20040076633A1/en not_active Abandoned
- 2001-09-20 MY MYPI20014415A patent/MY138978A/en unknown
- 2001-09-20 TW TW090123505A patent/TWI287453B/zh not_active IP Right Cessation
- 2001-09-20 CA CA002422863A patent/CA2422863A1/en not_active Abandoned
- 2001-09-20 ES ES01967535T patent/ES2309086T3/es not_active Expired - Lifetime
- 2001-09-20 JP JP2002528295A patent/JP2004509150A/ja active Pending
- 2001-09-20 AU AU8790801A patent/AU8790801A/xx active Pending
- 2001-09-20 WO PCT/GB2001/004207 patent/WO2002024225A1/en not_active Ceased
- 2001-09-20 AU AU2001287908A patent/AU2001287908B2/en not_active Ceased
- 2001-09-20 PL PL01360895A patent/PL360895A1/xx not_active Application Discontinuation
- 2001-09-20 KR KR1020037004041A patent/KR100876263B1/ko not_active Expired - Fee Related
- 2001-09-20 AT AT01967535T patent/ATE401097T1/de not_active IP Right Cessation
- 2001-09-20 CN CNB018186173A patent/CN1197620C/zh not_active Expired - Fee Related
- 2001-09-20 AR ARP010104453A patent/AR035586A1/es unknown
- 2001-09-20 NZ NZ524792A patent/NZ524792A/en not_active IP Right Cessation
-
2003
- 2003-03-19 NO NO20031274A patent/NO20031274L/no unknown
- 2003-03-20 ZA ZA200302231A patent/ZA200302231B/en unknown
-
2007
- 2007-06-19 US US11/764,814 patent/US20070248614A1/en not_active Abandoned
-
2010
- 2010-09-15 US US12/882,470 patent/US20110002953A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| GB0023008D0 (en) | 2000-11-01 |
| ZA200302231B (en) | 2004-05-05 |
| US20070248614A1 (en) | 2007-10-25 |
| NO20031274D0 (no) | 2003-03-19 |
| EP1318835A1 (de) | 2003-06-18 |
| HK1057700A1 (en) | 2004-04-16 |
| IL154947A0 (en) | 2003-10-31 |
| WO2002024225A1 (en) | 2002-03-28 |
| BR0113982A (pt) | 2003-08-19 |
| MY138978A (en) | 2009-08-28 |
| ES2309086T3 (es) | 2008-12-16 |
| DE60134866D1 (de) | 2008-08-28 |
| CN1473051A (zh) | 2004-02-04 |
| AU2001287908B2 (en) | 2005-06-30 |
| EP1318835B1 (de) | 2008-07-16 |
| MXPA03002453A (es) | 2003-06-19 |
| US20110002953A1 (en) | 2011-01-06 |
| JP2004509150A (ja) | 2004-03-25 |
| KR20040023566A (ko) | 2004-03-18 |
| CZ2003792A3 (cs) | 2004-12-15 |
| CN1197620C (zh) | 2005-04-20 |
| NZ524792A (en) | 2004-09-24 |
| KR100876263B1 (ko) | 2008-12-26 |
| NO20031274L (no) | 2003-05-19 |
| AR035586A1 (es) | 2004-06-16 |
| TWI287453B (en) | 2007-10-01 |
| PL360895A1 (en) | 2004-09-20 |
| AU8790801A (en) | 2002-04-02 |
| US20040076633A1 (en) | 2004-04-22 |
| HUP0301180A2 (hu) | 2004-03-01 |
| CA2422863A1 (en) | 2002-03-28 |
| HUP0301180A3 (en) | 2005-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE401097T1 (de) | Verwendung von imidazochinolinaminen als adjuvantien in dna-impfung | |
| DE69928763D1 (de) | Adjuvanzien zur Verwendung in Impfstoffen | |
| DE60111534D1 (de) | Alpha-acyl- und alpha-heteroatom-substituierte benzenacetamide verwendbar als glucokinase-aktivatoren | |
| DE60143301D1 (de) | Polyarylcarboxamide zur verwendung als lipidsenker | |
| NO20031483D0 (no) | Vaksine | |
| CY2013025I2 (el) | Ετερολογος εκφραση των πρωτεϊνων της neisseria | |
| DE50207852D1 (de) | Verwendung von fettalkoholethoxylaten als penetrationsförderer | |
| NO20024172D0 (no) | Vaksine | |
| EP1418940A4 (de) | Dna expressionsvektoren und verwendungsverfahren | |
| DE60101147D1 (de) | Mikroprozessor beständig gegen eine energie-analyse | |
| DE60102489D1 (de) | Eintauchbarer in situ Oxygenator | |
| EP1424392A4 (de) | Neue sekretionsproteine und dna dafür | |
| DE60126814D1 (de) | Inhalation von stickoxid | |
| DE60136400D1 (de) | Reinigung von hbv-Antigenen zur Verwendung in Impfstoffen | |
| DE50107834D1 (de) | Dispergierung von pigmenten in polyolefinen | |
| EP1369101A4 (de) | Kosmetisches w/ö/w-emulsionspräparat | |
| DE50006526D1 (de) | Verwendung von anti-idiotypischen antikörpern als impfstoffe gegen krebs | |
| DE60112148D1 (de) | Verwendung von (Per)fluoroetherverbindungen als Zusatzstoffe in Formulierungen zur Holzbehandlung | |
| EP1446130A4 (de) | Ehrlichia-canis-gene und -impfstoffe | |
| EP1293568A4 (de) | Protein und dessen dns | |
| DK1328289T3 (da) | Oxiderede proteiner og deres biologiske og terapuetiske aktivitet samt diagnostisk anvendelse ved hæmning af interaktion mellem oxiderede proteiner og CD36 | |
| DE60007360D1 (de) | Amorphe modifikation von torasemid | |
| EP1366056A4 (de) | Zubereitung von deoxynukleoside | |
| EP1490396A4 (de) | Immunogene hiv-peptide zur verwendung als reagentien und impfstoffe | |
| NO20030821D0 (no) | Gener og proteiner, og deres anvendelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |